INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on February 9, 2023, reporting events that occurred on February 3, 2023. The Company, incorporated in Nevada and trading on the OTCMKTS under the symbol "INVO," entered into significant financing agreements to secure working capital and general corporate purposes.
Key Financial Metrics and Transaction Details
The filing details a private placement and an equity purchase agreement rather than standard periodic financial results. Key transaction metrics include:
- Debenture Issuance: The Company issued a convertible debenture with an aggregate original principal amount of $300,000 for a purchase price of $270,000.
- Interest Rate: The debenture accrues interest at 8% per annum, payable at maturity on February 3, 2024.
- Conversion Terms: The debenture is convertible into common stock at a fixed price of $0.52 per share, subject to anti-dilution adjustments and a floor price.
- Warrant Issuance: A warrant was issued to the Buyer's general partner to purchase 150,000 shares of common stock at an exercise price of $0.75.
- Commitment Shares: 50,000 shares of common stock were issued as an inducement fee.
- Placement Agent Fee: Carter, Terry, & Company, Inc. received a cash fee of $21,600.
- Equity Line of Credit: The Company entered an agreement allowing it to direct the Buyer to purchase up to $10.0 million of common stock over a 24-month period (until February 3, 2025).
- Put Pricing: Shares sold under the equity line will be priced at 97% of the Market Price (defined as the lower of the lowest closing price over the prior 7 days or the lowest closing bid price the day before the put date).
Material Changes and Covenants
The filing introduces new debt obligations and potential equity dilution mechanisms:
- Beneficial Ownership Limits: Conversion and issuance are capped if the Buyer and affiliates would exceed 9.99% of outstanding common stock. A combined "Exchange Cap" limits total issuances under all related agreements to 19.99% of outstanding stock (approximately 2,436,045 shares) unless shareholder approval is obtained.
- Prepayment Terms: The Company may prepay the debenture at any time by paying 105% of the principal amount plus accrued interest.
- Proceeds Sweep: If the Company raises more than $2,000,000 in aggregate cash proceeds from any source, the Buyer has the right to require the Company to apply up to 50% of proceeds above this threshold to repay the debenture. If proceeds are raised via an Equity Line of Credit before reaching the $2,000,000 threshold, up to 25% of those proceeds may be applied to repayment.
- Registration Rights: The Company agreed to file a registration statement (Form S-3 or S-1) within 90 days of the transaction date to cover the resale of the debenture shares, warrant shares, and equity line shares.
Outlook, Risks, and Contingencies
Management intends to use the proceeds from these transactions for working capital and general corporate purposes. Key risks and contingencies identified in the filing include:
- Dilution Risk: The conversion of the debenture and exercise of warrants, combined with the equity line, could result in significant dilution to existing shareholders, subject to the 19.99% Exchange Cap.
- Liquidity Constraints: The "proceeds sweep" provision could restrict the Company's ability to utilize future capital raises for operations if the Buyer elects to enforce repayment rights.
- Default Triggers: Events of default include failure to make payments, bankruptcy, or failure to seek shareholder approval within 60 days of reaching the Exchange Cap. Upon default, the Buyer may require immediate cash redemption of the debenture.
- Market Price Volatility: The pricing mechanism for the equity line (97% of market price) exposes the Company to potential dilution if the stock price declines.
Investor Verification Checklist
- Verify the current outstanding share count to calculate the precise impact of the 19.99% Exchange Cap (cited as 2,436,045 shares).
- Confirm the Company's ability to file the required registration statement within the 90-day window to ensure liquidity for the Buyer.
- Monitor future capital raising activities to assess the likelihood of triggering the $2,000,000 proceeds sweep provision.
- Review the Company's cash burn rate to determine if the $270,000 net proceeds (after fees) are sufficient for stated working capital needs.
- Check for any subsequent filings regarding shareholder approval for issuances exceeding the Exchange Cap.